At Ceregene, researchers are pioneering a unique method to deliver neurotrophic factors, naturally occurring proteins essential during the early development of the brain and eye, to diseased and dying nerve cells.  The gene delivery technology is a highly targeted approach that could lead to significant breakthroughs for people with Parkinson’s and Alzheimer’s diseases, among other devastating illnesses.

Dr. Steve Sherwin, is co-founder and Chairman of the Board of Directors for Ceregene.  He is also Chairman of the Board of the trade association BIO (which sponsors this site).

He recently offered his thoughts to Ashley McMaster, the editor of BIO’s SmartBrief, on where the industry is headed in 2010.  This is a great snapshot of the hurdles the biotech industry will face.